November 21, 2024 02:17 PM EST

Jazz wins approval for bispecific in biliary tract cancer

Nicole DeFeudis

Editor

Jazz Pharmaceuticals earned an FDA approval on Wednesday for zanidatamab, the HER2-targeted bispecific antibody it picked up from Zymeworks for $50 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Jazz wins approval for bispecific in biliary tract cancer

Nicole DeFeudis

Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Amgen names Stanford geneticist and biotech founder to CSO post

Are programs with compounded GLP-1s safe for your population?

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

Nicole DeFeudis

Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Amgen names Stanford geneticist and biotech founder to CSO post

Are programs with compounded GLP-1s safe for your population?